RTI Surgical Announces Successful Resolution to FDA Warning Letter for Alachua, Fla. Facility

  RTI Surgical Announces Successful Resolution to FDA Warning Letter for
  Alachua, Fla. Facility

           Company Received Close-Out Letter Dated October 25, 2013

Business Wire

ALACHUA, Fla. -- October 29, 2013

RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company,
announced today that the company has received a close-out letter from the Food
and Drug Administration (FDA) verifying effective implementation of the
corrective actions put in place following the warning letter the company
received in October 2012.

The close-out letter follows an inspection in September 2013 by the FDA at the
Alachua, Fla. facility where inspectors noted the adequacy and effectiveness
of the voluntary corrective actions and acknowledged the significant
improvement in the overall environmental monitoring program. The receipt of
the close-out letter confirms that all items in the warning letter were
closed, and no new items, issues or FDA 483 observations were issued as part
of the follow-up inspection.

“Although patient safety was never in question, we are pleased to have
received a close-out letter and for the successful resolution to the warning
letter,” said Brian K. Hutchison, president and chief executive officer. “We
take very seriously our commitment to patient safety and the confidence of
surgeons who use our implants and we are committed to ensuring that we have
the most robust environmental monitoring and quality control procedures in our
industry. With more than five million implants distributed with zero incidence
of implant-associated infection, we maintain our status as the industry leader
in patient safety.”

About RTI Surgical Inc.

RTI is a leading global surgical implant company providing surgeons with safe
biologic, metal and synthetic implants. Committed to advancing science, safety
and innovation, RTI’s implants are used in sports medicine, general surgery,
spine, orthopedic, trauma and cardiothoracic procedures and are distributed in
nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four
manufacturing facilities throughout the U.S. and Europe. RTI is accredited in
the U.S. by the American Association of Tissue Banks and is a member of
AdvaMed. For more information, please visit www.rtix.com.

Forward-Looking Statement

This communication contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s current expectations, estimates and
projections about our industry, our management's beliefs and certain
assumptions made by our management. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," variations of such words
and similar expressions are intended to identify such forward-looking
statements. In addition, except for historical information, any statements
made in this communication about anticipated financial results, growth rates,
new product introductions, future operational improvements and results or
regulatory actions or approvals or changes to agreements with distributors
also are forward-looking statements. These statements are not guarantees of
future performance and are subject to risks and uncertainties, including the
risks described in public filings with the U.S. Securities and Exchange
Commission (SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements. Copies of
the company's SEC filings may be obtained by contacting the company or the SEC
or by visiting RTI's website at www.rtix.com or the SEC's website at


RTI Surgical Inc.
Jenny Highlander, APR, 386-418-8888
Manager, Global Communications
Press spacebar to pause and continue. Press esc to stop.